Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer

[1]  R. Bosotti,et al.  Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer , 2015, Journal of the National Cancer Institute.

[2]  R. Labianca,et al.  Assessment of a HER2 scoring system for colorectal cancer: results from a validation study , 2015, Modern Pathology.

[3]  A. Drilon,et al.  29LBA Entrectinib (RXDX-101), an oral pan-Trk, ROS1, and ALK inhibitor in patients with advanced solid tumors harboring gene rearrangements , 2015 .

[4]  Beatriz Bellosillo,et al.  Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients , 2015, Nature Medicine.

[5]  Joon-Oh Park,et al.  Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screening , 2015, Oncotarget.

[6]  V. Torri,et al.  Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients (mCRC): The HERACLES trial. , 2015 .

[7]  Marco Beccuti,et al.  The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets , 2015, Nature Communications.

[8]  G. von Heijne,et al.  Tissue-based map of the human proteome , 2015, Science.

[9]  M. Berger,et al.  Pilot Trial of Combined BRAF and EGFR Inhibition in BRAF-Mutant Metastatic Colorectal Cancer Patients , 2015, Clinical Cancer Research.

[10]  A. Iafrate,et al.  Anchored multiplex PCR for targeted next-generation sequencing , 2014, Nature Medicine.

[11]  Andrea Lombardi Borgia,et al.  The TPM3‐NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition , 2014, Molecular oncology.

[12]  P. David Pearson,et al.  448PDRXDX-101, AN ORAL PAN-TRK, ROS1, AND ALK INHIBITOR, IN PATIENTS WITH ADVANCED SOLID TUMORS WITH RELEVANT MOLECULAR ALTERATIONS. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  A. Shaw,et al.  ALK inhibitors in non-small cell lung cancer: crizotinib and beyond. , 2014, Clinical advances in hematology & oncology : H&O.

[14]  S. Ramón-Maiques,et al.  Structure, functional characterization, and evolution of the dihydroorotase domain of human CAD. , 2014, Structure.

[15]  Dara L Aisner,et al.  ROS1 and ALK Fusions in Colorectal Cancer, with Evidence of Intratumoral Heterogeneity for Molecular Drivers , 2013, Molecular Cancer Research.

[16]  Andrea Bertotti,et al.  Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. , 2013, Cancer discovery.

[17]  A. Isacchi,et al.  Abstract 2092: The ALK inhibitor NMS-E628 also potently inhibits ROS1 and induces tumor regression in ROS-driven models . , 2013 .

[18]  A. Chinnaiyan,et al.  The nucleotide synthesis enzyme CAD inhibits NOD2 antibacterial function in human intestinal epithelial cells. , 2012, Gastroenterology.

[19]  E. Grande,et al.  Targeting Oncogenic ALK: A Promising Strategy for Cancer Treatment , 2011, Molecular Cancer Therapeutics.

[20]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.